AbbVie is trading 3.8% down at $247.52 after trimming its 2026 profit outlook to fund a $10.9 billion acquisition of Apogee and accelerate pipeline investment.
- The company lowered its full-year adjusted EPS guidance, which is weighing on shares despite reporting double-digit revenue and earnings growth.
- Strong Q2 performance was primarily driven by the immunology portfolio, but investor focus has shifted to the long-term financial impact of the acquisition and increased R&D spending.